Cytel: Global experts in Market Access, HEOR & RWE

At Cytel, we provide the deep insights and expertise necessary for making confident development decisions. Our global team helps generate evidence that complements traditional randomized clinical trials, accelerates submissions, expands indications, and supports health-economic decision-making.

We are excited to see you at ISPOR US 2024 on May 5-8, 2024.

This year, visit us at Booth #1018 to connect with our HEOR & RWE experts on topics such as RWE and Health Disparities in HTAs, Quantitative Bias Analysis, RWE Sources in HTA Submissions and more.

Fill out the form to pre-book a meeting with the Cytel team to learn more about our innovative offerings in Market Access, HEOR & RWE.

Meet with us at ISPOR US

HEOR & RWE Focused Blogs

Key Elements and Implications of the Draft EU JCA Implementing Act

Written by Lydia Vinals, PhD, and Grammati Sarri, PhD The draft Implementing Act of the EU Health Technology Assessment...

Unravelling PICO: The Pillars of the European Joint Clinical Assessment

The European Union (EU) health technology assessment (HTA) regulation aims to improve the availability of innovative...

Mind the Health Gap: Is It Time to Reliably Measure the Impact of Health Inequity in Product Development and Assessment? Yes, It Is.

Written by Grammati Sarri and Yannis Jemiai The spotlight for this year’s World Evidence-Based Healthcare Day (EBHC)...

Real World & Advanced Analytics

Through our advanced analytics, Cytel provides the richer, deeper insights necessary for making confident development decisions. We generate evidence which complements traditional randomized clinical trials, accelerates submissions, expands indications, and supports health-economic decision-making.

Click to learn more about our HEOR, RWE, LiveSLR, and more offerings.

Cytel Market Access, HEOR & RWE